Overview
Andrew J. Warmus focuses his practice on domestic and cross-border mergers and acquisitions, joint ventures, and other strategic transactional matters. He has broad experience representing private equity firms and other financial sponsors, multinational public companies, private companies, and founders in material and transformative transactions across multiple industries, with significant experience in the life sciences sector, including pharmaceuticals, diagnostics, and medical devices.
Andrew advises buyers and sellers in acquisitions, divestitures, and strategic transactions often involving complex, multijurisdictional carve-out transactions in regulated industries. He also provides counsel to several portfolio companies on a wide range of matters and builds and leads bespoke teams to deliver commercial solutions.
Andrew is a member of the Firm’s Cross-Border Steering Committee.
Results
- Represented Select Equity Group L.P. in multiple platform company acquisitions and subsequent add-on transactions
- Advised Alnair Therapeutics, Inc. on various matters, including corporate governance, licensing, and venture finance
- Represented Performant Capital in multiple platform company acquisitions and add-on transactions
- Represented Lindsay Goldberg in multiple transactions and governance matters for its Ultra Clean Express Car Wash and Dash Car Wash platform
- Represented Sojourner Consumer Partners in connection with multiple planned acquisitions and venture strategies
- Assisted Spaulding Ridge, a leading advisory and technology implementation firm, with its formation, multiple acquisitions, and in connection with its international expansion and further growth
- Represented Further Point Enterprises in the acquisition of Foxtrot assets and related corporate governance and equity investment matters
- Represented Kin Group Pty Ltd in multiple matters, including its investment in Remedy Drinks International Limited
- Represented Walgreens Co. in connection with the formation of AllianceRx Walgreens Prime, a strategic joint venture between Walgreens Co. and Prime Therapeutics to create one of the largest specialty and home delivery pharmacies in the United States*
- Represented Abbott Laboratories in its sale of the St. Jude Medical Angio-Seal and FemoSeal vascular closure devices business to Terumo Corporation*
- Represented Abbott Laboratories in the divestiture of Alere Inc.’s Triage® MeterPro cardiovascular and toxicology business and B-type Naturietic Peptide assay business run on Beckman Coulter analyzers*
- Represented Abbott Laboratories in connection with the sale of its non-US developed markets branded generics pharmaceuticals business to Mylan N.V. in exchange for an approximately 21% equity interest in Mylan*
- Represented Safran S.A. in connection with its strategic joint venture with The Boeing Company*
- Represented ARIAD Pharmaceuticals, Inc. in the divestiture of its European operations to Incyte Corporation*
- Represented Fortune Brands Innovations, Inc. in connection with multiple early-stage investments and commercial arrangements with startup companies*
- Represented CommScope Holding Company, Inc. in its acquisition of TE Connectivity’s telecom, enterprise, and wireless business*
- Represented F45 Training, Inc. in connection with the equity investment by an investor group led by Mark Wahlberg*
- Represented MiddleGround Capital in its acquisition of Shiloh Industries, Inc. and multiple related transactions*
*Matter handled prior to joining McDermott.
Recognitions
- Legal 500 USA, Recommended Lawyer, 2022
Credentials
Education
University of Chicago Booth School of Business, MBA, 2011
Marquette University Law School, JD, 2006
Colorado State University, BS, 2002
Admissions
Illinois
Wisconsin
